These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7089575)

  • 1. Cysteamine: a potent and specific depletor of pituitary prolactin.
    Millard WJ; Sagar SM; Landis DM; Martin JB
    Science; 1982 Jul; 217(4558):452-4. PubMed ID: 7089575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cysteamine induces depletion of both immunological and biological prolactin activity in the anterior pituitary and blood of the rat.
    Millard WJ; Sagar SM; Simpkins JW; Owens RE; Badger TM; Friesen HG; Martin JB
    Endocrinology; 1983 Dec; 113(6):2161-7. PubMed ID: 6641630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cysteamine depletes prolactin in young and old hyperprolactinemic rats.
    Simpkins JW; Estes KS; Millard WJ; Sagar SM; Martin JB
    Endocrinology; 1983 May; 112(5):1889-91. PubMed ID: 6832077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a D1 dopamine receptor, not linked to adenylate cyclase, on lactotroph cells.
    Schoors DF; Vauquelin GP; De Vos H; Smets G; Velkeniers B; Vanhaelst L; Dupont AG
    Br J Pharmacol; 1991 Aug; 103(4):1928-34. PubMed ID: 1833020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteamine-induced depletion of somatostatin and prolactin.
    Millard WJ; Sagar SM; Martin JB
    Fed Proc; 1985 Jun; 44(9):2546-50. PubMed ID: 2860016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One minute of bromocriptine irreversibly inhibits prolactin release for hours.
    Cronin MJ; Evans WS; Thorner MO
    Eur J Pharmacol; 1984 Mar; 99(1):85-90. PubMed ID: 6723793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary site of action of endothelin: selective inhibition of prolactin release in vitro.
    Samson WK; Skala KD; Alexander BD; Huang FL
    Biochem Biophys Res Commun; 1990 Jun; 169(2):737-43. PubMed ID: 2113384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteamine depletes prolactin (PRL) but does not alter the structure of PRL-containing granules in the anterior pituitary.
    Weinstein LA; Landis DM; Sagar SM; Millard WJ; Martin JB
    Endocrinology; 1984 Oct; 115(4):1543-50. PubMed ID: 6479101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromocriptine inhibits growth hormone release from rat pituitary cells in primary culture.
    Cronin MJ; Thorner MO; Hellmann P; Rogol AD
    Proc Soc Exp Biol Med; 1984 Feb; 175(2):191-5. PubMed ID: 6694976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine-induced inhibition of prolactin release from cultured adenohypophysial cells: spare receptors for dopamine.
    Shin SH
    Life Sci; 1978 Jan; 22(1):67-73. PubMed ID: 625189
    [No Abstract]   [Full Text] [Related]  

  • 11. The mechanism of action of cysteamine in depleting prolactin immunoreactivity.
    Sagar SM; Millard WJ; Martin JB; Murchison SC
    Endocrinology; 1985 Aug; 117(2):591-600. PubMed ID: 3926458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chlorpromazine, haloperidol, metoclopramide and domperidone release prolactin through dopamine antagonism at low concentrations but paradoxically inhibit prolactin release at high concentrations.
    Besser GM; Delitala G; Grossman A; Stubbs WA; Yeo T
    Br J Pharmacol; 1980; 71(2):569-73. PubMed ID: 6110459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine and bromocriptine inhibit cyclic AMP accumulation in the anterior pituitary: the effect of cholera toxin.
    Cronin MJ; Thorner MO
    J Cyclic Nucleotide Res; 1982; 8(4):267-75. PubMed ID: 6300209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central administration of orexin A suppresses basal and domperidone stimulated plasma prolactin.
    Russell SH; Kim MS; Small CJ; Abbott CR; Morgan DG; Taheri S; Murphy KG; Todd JF; Ghatei MA; Bloom SR
    J Neuroendocrinol; 2000 Dec; 12(12):1213-8. PubMed ID: 11106980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacy of cysteamine in depleting prolactin immunoreactivity in different hyperprolactinemic animal models.
    Millard WJ; Romano TM
    Life Sci; 1991; 49(22):1635-42. PubMed ID: 1943468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of amantadine on prolactin secretion, pituitary DNA synthesis and 3H-spiperone binding in male estrogen-treated rats.
    Krawczyk Z; Lyson K; Stawowy A; Pisarek H; Stepien H
    Neuroendocrinology; 1990 Jun; 51(6):632-6. PubMed ID: 2141919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cysteamine on suckling-induced prolactin secretion in the rat.
    Millard WJ; O'Sullivan D; Riskind PN
    Life Sci; 1987 Nov; 41(20):2255-60. PubMed ID: 3683075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological concentrations of dopamine decrease adenosine 3',5'-monophosphate levels in cultured rat anterior pituitary cells and enriched populations of lactotrophs: evidence for a causal relationship to inhibition of prolactin release.
    Swennen L; Denef C
    Endocrinology; 1982 Aug; 111(2):398-405. PubMed ID: 6284477
    [No Abstract]   [Full Text] [Related]  

  • 19. The 22K variant of rat prolactin: evidence for identity to prolactin-(1-173), storage in secretory granules, and regulated release.
    Anthony PK; Stoltz RA; Pucci ML; Powers CA
    Endocrinology; 1993 Feb; 132(2):806-14. PubMed ID: 8425495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian steroids modulate the release of dopamine into hypophysial portal blood and the density of anterior pituitary [3H]spiperone-binding sites in ovariectomized rats.
    Pilotte NS; Burt DR; Barraclough CA
    Endocrinology; 1984 Jun; 114(6):2306-11. PubMed ID: 6723585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.